| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-04-10 | JOHNSON & JOHNSON | Contineum Therapeutics, Inc. | 1,979,173 | 10.7% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | JOHNSON & JOHNSON | 229,372,559 | 9.5% | EDGAR |
| SC 13G/A | 2024-02-02 | JOHNSON & JOHNSON | Nanobiotix S.A. | 5,623,816 | 11.9% | EDGAR |
| SC 13G/A | 2024-02-02 | JOHNSON & JOHNSON | CVRx, Inc. | 4,109,336 | 19.2% | EDGAR |
| SC 13G/A | 2024-02-02 | JOHNSON & JOHNSON | BiomX Inc. | 2,113,402 | 4.6% | EDGAR |
| SC 13G/A | 2024-01-30 | STATE STREET CORP | JOHNSON & JOHNSON | - | 5.5% | EDGAR |
| SC 13G/A | 2024-01-26 | BlackRock Inc. | JOHNSON & JOHNSON | 186,308,341 | 7.7% | EDGAR |
| SC 13G | 2024-01-24 | JOHNSON & JOHNSON | Kenvue Inc. | 182,329,550 | 9.5% | EDGAR |
| SC 13G/A | 2023-02-10 | STATE STREET CORP | JOHNSON & JOHNSON | - | 5.4% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | JOHNSON & JOHNSON | 246,826,621 | 9.4% | EDGAR |
| SC 13G/A | 2023-01-31 | BlackRock Inc. | JOHNSON & JOHNSON | 198,802,769 | 7.6% | EDGAR |
| SC 13G/A | 2023-01-27 | JOHNSON & JOHNSON | Fusion Pharmaceuticals Inc. | 3,670,516 | 8.2% | EDGAR |
| SC 13G/A | 2023-01-11 | JOHNSON & JOHNSON | Protagonist Therapeutics, Inc | 2,449,183 | 5.0% | EDGAR |
| SC 13G/A | 2022-11-14 | JOHNSON & JOHNSON | MeiraGTx Holdings plc | 6,641,064 | 13.7% | EDGAR |
| SC 13G/A | 2022-02-14 | STATE STREET CORP | JOHNSON & JOHNSON | - | 5.5% | EDGAR |
| SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | JOHNSON & JOHNSON | 234,782,632 | 8.9% | EDGAR |
| SC 13G | 2022-02-07 | JOHNSON & JOHNSON | CVRx, Inc. | 4,109,573 | 19.6% | EDGAR |
| SC 13G/A | 2022-02-01 | BlackRock Inc. | JOHNSON & JOHNSON | 200,021,352 | 7.6% | EDGAR |
| SC 13G/A | 2022-02-01 | JOHNSON & JOHNSON | PhaseBio Pharmaceuticals Inc | 1,607,044 | 3.3% | EDGAR |
| SC 13G | 2021-02-12 | STATE STREET CORP | JOHNSON & JOHNSON | - | 5.5% | EDGAR |